Pancreatic cancer is one of the deadliest forms of cancer, largely because it’s so difficult to catch early. By the time it’s ...

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood ...

achieving 95% sensitivity and 98% specificity for pancreatic cancer detection. Mainz Biomed N.V. has announced an exclusive licensing agreement with Liquid Biosciences to access a portfolio of ...

Mainz Biomed has the exclusive rights to develop a test for early pancreatic cancer detection using Liquid Biosciences' biomarkers.

BERKELEY, Calif. and MAINZ, Germany, March 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”) , a molecular ...

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood ... Algorithm Based on Liquid Biosciences EMERGE Platform ...

BERKELEY, Calif. and MAINZ, Germany, March 13, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”) , a molecular genetics diagnostic company specializing in the ...

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood ... Algorithm Based on Liquid Biosciences EMERGE Platform ...